Health Minister Vaughan Gething, has set out his vision for cutting edge precision medicine to improve health and deliver a sustainable future for NHS Wales.
During, a visit to the Rutherford Cancer Centre in Newport, Mr Gething announced new strategies to transform pathology and precision therapeutics in Wales.
“To address future challenges from the increasing burden of disease we must focus more on prevention, early detection and personalised targeted treatments. Precision medicine will increasingly support a more personalised approach to health and care.
“In Wales, we are already making progress in the field of precision medicine and I am confident that we can be a global player in the race to harness its potential. NHS Wales is on the cusp of realising the significant benefits that can be delivered by advances in precision medicine for patients by offering the right test or treatment at the right time.
“Our long term plan 'A Healthier Wales' recognises the importance of moving towards earlier detection and intervention to prevent illness and prolong independence.”
The Minister explained the Welsh Government had a clear vision for harnessing technology to deliver precision medicine in diagnostics and therapy that will ensure a sustainable future for NHS Wales.
“The Rutherford Cancer Centre in Newport, which was the first facility in the UK to offer proton beam therapy for cancer patients, is an excellent example of the development of new cancer therapies, here in Wales. It’s a perfect illustration of how we are working collaboratively to deliver technological innovations to improve treatment,” he said.
“Today I have published our Statement of Intent for Advanced Therapeutic Medicinal Products, which sets out how we will deliver precision therapeutics, like new cell therapies, in Wales.
“Alongside this I have published a Statement of Intent to transform pathology services. All this builds on our recent investment in diagnostic services such as the new Imaging Academy for Wales.
“In this financial year, I am pleased to provide additional funding of £2.3m to support the delivery of new genetic tests together with a further £2m to support national plans for transforming diagnostic, health science and advanced therapeutic medicinal product services in NHS Wales.”